Insight Molecular Diagnostics Inc. (IMDX) vs Outlook Therapeutics, Inc. (OTLK)
A side-by-side comparison of Insight Molecular Diagnostics Inc. and Outlook Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
IMDX
Insight Molecular Diagnostics Inc.
$3.45HealthcareDelayed quote: Oct 6, 2026, 2:19 PM EDT
OTLK
Outlook Therapeutics, Inc.
$0.58HealthcareDelayed quote: Oct 6, 2026, 2:20 PM EDT
Total return — IMDX vs OTLK
growth of $100 · dividends reinvested · last 10yIMDX -96.9% (-29.4%/yr)OTLK -99.9% (-50.4%/yr)IMDX compounded faster over this window
Log scale — wide-divergence pair
IMDX OTLK
IMDX vs OTLK: by the numbers
- •IMDX is the larger company ($111M vs $108M market cap).
- •Both run net losses; IMDX's is the smaller (-2955.63% vs -4416.22% net margin).
Metrics side by side
Valuation
| Metric | IMDX | OTLK |
|---|---|---|
| P/S ratio | 66.71 | N/A |
Profitability
| Metric | IMDX | OTLK |
|---|---|---|
| Gross margin | 11.17% | 46.49% |
| Operating margin | -754.08% | -4744.25% |
| Net margin | -2955.63% | -4416.22% |
| ROIC | -223.06% | -352.19% |
Growth (annualized)
| Metric | IMDX | OTLK |
|---|---|---|
| Revenue CAGR (5Y) | 27.24% | N/A |
| Total return CAGR (5Y) | -44.39% | -57.40% |
Frequently asked
- How have IMDX and OTLK total returns compared?
- Over the past 10 years, IMDX delivered -29.11% and OTLK delivered -50.38% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Insight Molecular Diagnostics ROEOutlook Therapeutics ROEInsight Molecular Diagnostics operating marginOutlook Therapeutics operating marginInsight Molecular Diagnostics revenue growthOutlook Therapeutics revenue growthInsight Molecular Diagnostics free cash flowOutlook Therapeutics free cash flow
Insight Molecular Diagnostics & Outlook Therapeutics appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.